Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Verastem Inc (VSTM)
Verastem Inc (VSTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,228
  • Shares Outstanding, K 25,267
  • Annual Sales, $ 2,600 K
  • Annual Income, $ -73,810 K
  • 60-Month Beta 0.58
  • Price/Sales 70.47
  • Price/Cash Flow N/A
  • Price/Book 2.28
Trade VSTM with:

Options Overview Details

View History
  • Implied Volatility 88.22% ( -12.39%)
  • Historical Volatility 60.59%
  • IV Percentile 20%
  • IV Rank 4.08%
  • IV High 973.60% on 03/14/23
  • IV Low 50.56% on 09/14/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 29
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 1,801
  • Open Int (30-Day) 1,741

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.77
  • Number of Estimates 3
  • High Estimate -0.67
  • Low Estimate -0.84
  • Prior Year -0.96
  • Growth Rate Est. (year over year) +19.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.94 +27.78%
on 11/16/23
7.79 -2.57%
on 12/06/23
+0.53 (+7.51%)
since 11/07/23
3-Month
5.94 +27.78%
on 11/16/23
10.30 -26.29%
on 09/18/23
-2.24 (-22.79%)
since 09/07/23
52-Week
3.87 +96.12%
on 12/28/22
15.18 -50.00%
on 05/30/23
+2.79 (+58.12%)
since 12/07/22

Most Recent Stories

More News
Verastem: Q3 Earnings Snapshot

Verastem: Q3 Earnings Snapshot

VSTM : 7.59 (+2.43%)
Verastem: Q2 Earnings Snapshot

Verastem: Q2 Earnings Snapshot

VSTM : 7.59 (+2.43%)
Markets Today: Stocks Firm on Hopes for Additional Chinese Stimulus

Morning Markets June E-Mini S&P 500 futures (ESM23 ) this morning are up +0.19%, and June Nasdaq 100 E-Mini futures (NQM23 ) are up +0.37%. U.S. stock index futures this morning are moderately higher....

ESZ23 : 4,587.75 (-0.04%)
NQZ23 : 16,011.25 (-0.17%)
ADBE : 608.78 (+2.20%)
NVDA : 465.96 (+2.40%)
IRBT : 38.69 (+1.23%)
SQSP : 27.77 (-1.56%)
MU : 73.65 (+0.71%)
COHR : 40.42 (+3.67%)
LC : 6.83 (+1.94%)
PLTR : 17.22 (+0.53%)
TIGO : 16.65 (+0.42%)
SOFI : 7.96 (+0.89%)
Stock Index Futures Move Higher as Investors Weigh Interest Rate Outlook, China Stimulus Hopes Boost Sentiment

June S&P 500 futures (ESM23) are up +0.10%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.30% this morning after three major U.S. benchmark indices rallied on Thursday as a series of economic data...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
DPZ : 402.00 (+2.41%)
LEN : 137.47 (+1.55%)
MSFT : 370.95 (+0.58%)
META : 326.59 (+2.88%)
KR : 44.80 (+0.58%)
TPK.LN : 786.200 (-0.05%)
ADBE : 608.78 (+2.20%)
SPCE : 2.23 (+10.40%)
SQSP : 27.77 (-1.56%)
SOFI : 7.96 (+0.89%)
Markets Jump to 14-Month highs

Morning Markets The S&P 500 Index ( $SPX ) ( SPY ) is up +0.47%, the Dow Jones Industrials Index ( $DOWI ) ( DIA ) is up $0.69%, and the Nasdaq 100 Index ( $IUXX ) ( QQQ ) is up +0.37%. U.S. stock index...

ESZ23 : 4,587.75 (-0.04%)
NQZ23 : 16,011.25 (-0.17%)
TSLA : 242.64 (+1.37%)
NVDA : 465.96 (+2.40%)
AMD : 128.37 (+9.89%)
MCHP : 85.81 (+2.62%)
MRVL : 52.19 (+3.49%)
INTC : 42.15 (+2.13%)
ANET : 215.29 (+0.89%)
EDIT : 10.90 (-1.89%)
SOFI : 7.96 (+0.89%)
COHR : 40.42 (+3.67%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 0.3293 (+12.16%)
DAWN : 12.43 (+1.14%)
SWTX : 30.50 (+5.14%)
VSTM : 7.59 (+2.43%)
KNTE : 2.21 (+1.38%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 0.3293 (+12.16%)
SWTX : 30.50 (+5.14%)
DAWN : 12.43 (+1.14%)
VSTM : 7.59 (+2.43%)
KNTE : 2.21 (+1.38%)
Verastem: Q1 Earnings Snapshot

Verastem: Q1 Earnings Snapshot

VSTM : 7.59 (+2.43%)
Verastem Oncology to Participate in Upcoming Investor Conferences

Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming...

VSTM : 7.59 (+2.43%)
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting

Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that an abstract highlighting updated interim results from...

VSTM : 7.59 (+2.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 8.25
2nd Resistance Point 7.98
1st Resistance Point 7.79
Last Price 7.59
1st Support Level 7.33
2nd Support Level 7.06
3rd Support Level 6.87

See More

52-Week High 15.18
Fibonacci 61.8% 10.86
Fibonacci 50% 9.52
Fibonacci 38.2% 8.19
Last Price 7.59
52-Week Low 3.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar